NCT05557045 - A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Biotech Hunter

Enrollment

332

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2028

Conditions

Advanced CancerMetastatic CancerSolid Tumor

Interventions

DRUG

JZP815

JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.

Trial Locations (8)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

19107

RECRUITING

Sidney Kimmel Cancer Center, Philadelphia

32827

RECRUITING

Florida Cancer Specialists - Lake Nona, Orlando

34232

RECRUITING

Florida Cancer Specialists - Sarasota, Sarasota

37203

RECRUITING

Tennessee Oncology - Nashville, Nashville

60637

RECRUITING

University of Chicago, Chicago

73104

RECRUITING

Oklahoma University, Oklahoma City

80218

RECRUITING

SCRI HealthOne, Denver